Armistice Capital’s Calidi Biotherapeutics CLDI Stock Holding History

Armistice Capital’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54,938	Closed	-$210K	–	350
2026 Q1	$210K	Buy	+54,938	New	+$660K	﹤0.01%	225
2025 Q3	–	Sell	-4,125	Closed	-$182K	–	347
2025 Q2	$182K	Sell	4,125 -13,177	-76%	-$1.02M	﹤0.01%	183
2025 Q1	$1.88M	Buy	+17,302	New	+$3.16M	0.03%	150

Other funds holding CLDI

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Armistice Capital's CLDI Position: Q2 2026 in Review

Armistice Capital sold out of Calidi Biotherapeutics (CLDI) in Q2 2026, closing a stake of 54,938 shares — an estimated $210K sold.

Armistice Capital first reported a position in CLDI in Q1 2025 and held it in 3 quarters. The position peaked at $1.88M in Q1 2025. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

Armistice Capital reported no remaining Calidi Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 54,938 Calidi Biotherapeutics shares in Q2 2026, an estimated $210K.
Armistice Capital first reported a position in Calidi Biotherapeutics in Q1 2025 and held it in 3 quarters.
Armistice Capital's Calidi Biotherapeutics position peaked at $1.88M in Q1 2025.
22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.